METIS Trademark

Trademark Overview


On Friday, June 25, 2021, a trademark application was filed for METIS with the United States Patent and Trademark Office. The USPTO has given the METIS trademark a serial number of 90795166. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Friday, November 22, 2024. This trademark is owned by Metis Pharmaceuticals US Inc.. The METIS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

pharmaceutical preparations for target delivery of small molecules, RNA and gene therapies for central nervous system diseases, liver diseases, lung diseases, cancer, immune system diseases, rare diseases caused by genetic anomalies, kidney diseases, gastrointestinal diseases, and infectious diseases; drug delivery agents in the form of lipid nanoparticles, solid dispersion solutions, gel, self-emulsifying subcutaneous injections, and sustained and controlled release formulations that facilitate the delivery of pharmaceutical preparations and improve the patients' medication experience

pharmaceutical research and development services

General Information


Serial Number90795166
Word MarkMETIS
Filing DateFriday, June 25, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateFriday, November 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 22, 2022

Trademark Statements


Goods and Servicespharmaceutical preparations for target delivery of small molecules, RNA and gene therapies for central nervous system diseases, liver diseases, lung diseases, cancer, immune system diseases, rare diseases caused by genetic anomalies, kidney diseases, gastrointestinal diseases, and infectious diseases; drug delivery agents in the form of lipid nanoparticles, solid dispersion solutions, gel, self-emulsifying subcutaneous injections, and sustained and controlled release formulations that facilitate the delivery of pharmaceutical preparations and improve the patients' medication experience
Goods and Servicespharmaceutical research and development services

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 19, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, September 20, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMETIS THERAPEUTICS INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCAMBRIDGE, MA 02140

Party NameMETIS THERAPEUTICS INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressCAMBRIDGE, MA 02142

Party NameMetis Pharmaceuticals US Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Thursday, September 9, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 8, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 8, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 8, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, March 8, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, March 17, 2022ASSIGNED TO EXAMINER
Thursday, March 17, 2022NON-FINAL ACTION WRITTEN
Thursday, March 17, 2022NON-FINAL ACTION E-MAILED
Thursday, March 17, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 13, 2022AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Monday, September 19, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, September 19, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 20, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 19, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, October 19, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, October 19, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, October 19, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, October 19, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 2, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 22, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 22, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 17, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, June 28, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, June 28, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, June 28, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, July 14, 2023SOU TEAS EXTENSION RECEIVED
Friday, July 14, 2023SOU EXTENSION 1 FILED
Friday, July 14, 2023SOU EXTENSION 1 GRANTED
Tuesday, July 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 26, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, December 26, 2023SOU EXTENSION 2 FILED
Tuesday, December 26, 2023SOU EXTENSION 2 GRANTED
Thursday, December 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 11, 2024SOU TEAS EXTENSION RECEIVED
Thursday, July 11, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 11, 2024SOU EXTENSION 3 FILED
Thursday, July 11, 2024SOU EXTENSION 3 GRANTED
Friday, November 22, 2024SOU TEAS EXTENSION RECEIVED
Friday, November 22, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 22, 2024SOU EXTENSION 4 FILED
Friday, November 22, 2024SOU EXTENSION 4 GRANTED